◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1875

BioDlink International Company Limited (1875) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

BioDlink International Company Limited (1875) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 579 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 1875 reported CNY 748M in revenue and (CNY 100M) in net income.

BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally.

Interactive charts & full statements →

1875 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 748MCNY 1.1BCNY 781MCNY 442M
Gross ProfitCNY 389MCNY 782MCNY 574MCNY 371M
Operating Income (EBIT)(CNY 81M)CNY 37M(CNY 21M)(CNY 39M)
Net Income(CNY 100M)CNY 35M(CNY 38M)(CNY 50M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1875 Free Cash Flow History

1875 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.3BCNY 1.5BCNY 1.4BCNY 1.3B
Total LiabilitiesCNY 634MCNY 779MCNY 739MCNY 547M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1875 viewer.

Other Companies in Biotechnology

← 1873All “0-9” companies1876 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.